Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
-
War's impact on fertilisers stirs food producer fears
-
US inflation surges to 3.3% as Iran war impact bites
-
Thais fete new year with family despite fuel price spike
-
Scheffler scrambles, Rose stumbles early at Masters
-
On Iran truce, all sides want bigger China role, but does China?
-
Sinner eases into Monte Carlo semi-final against Zverev
-
Inter skipper Martinez suffers calf injury
-
Ukrainians sceptical as Kremlin orders Easter truce
-
Arteta urges Arsenal to pile pressure on Man City in title race
-
Pay fears grow for US security workers in shutdown
-
Hungary rivals rally crowds in closing strait of election campaign
-
Swede goes on trial for pressuring wife to sell sex
-
US inflation surges 3.3% as Iran war impact bites
-
Vance warns Iran not to 'play' US at talks in Pakistan
-
Fernandez remains out despite apology: Chelsea boss Rosenior
-
Dortmund defender Schlotterbeck extends contract until 2031
-
De Zerbi vows to save troubled Spurs from relegation
-
Antwerp port reopens to North Sea shipping after oil spill
-
Stocks mixed, oil steadies on guarded optimism for Iran ceasefire
-
Sinner eases into Monte Carlo semi-finals
-
France's Macron talks war, peace and basketball with Pope Leo
-
Fernandez apologised over comments about his future: Chelsea's Rosenior
-
Coach Spalletti signs new Juve deal until 2028
-
AI chatbots offer children harm as if it were help, says activist
-
'Grumpy' Guardiola wants Silva to stay at Man City for life
-
Zverev beats Fonseca to reach Monte Carlo semi-finals
-
Scheffler, Rose to chase McIlroy with early Masters starts
-
Celine Dion's Paris concerts promise to spin the money on and on
-
Stocks climb, oil steadies on guarded optimism over Iran war ceasefire
-
Irish govt to meet farmers, hauliers over fuel cost fears
-
Injured Bayern starlet Karl to miss Real return leg
-
US-Iran talks in Pakistan uncertain as sides trade accusations
-
Oil spill snarls shipping traffic in Antwerp port
-
Giving birth in a shelter in Israel
-
Five things to know about the planned Iran-US talks in Islamabad
-
Slot feels 'complete support' from Liverpool chiefs despite slump
-
Kyiv books tentative diplomatic coup with Iran war forays
-
Teenager shines as Britain seize control of BJK Cup tie with Australia
-
Chinese, Taiwanese will unite, Xi tells Taiwan opposition leader
-
Sleepy seal diverts traffic in Australian seaside town
-
Artemis astronauts to shed light on space health risks
-
Pakistan prepares to host US-Iran talks, as Lebanon fighting continues
-
Vaccine gaps fuel Bangladesh's deadly measles crisis
-
Fish furore fuels fierce election in India's West Bengal
-
Coachella kicks off with headliners Sabrina Carpenter, Bieber and Karol G
-
Myanmar junta chief sworn in as president
-
Exiled cartoonists give voice to Iran's silenced millions
-
In Pakistan's mediation to end Mideast war, China may hold the key
-
Knicks stay in hunt with late win over rival Celtics
-
'Sartorial diplomacy' on show in expo of late UK queen's fashion
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
FRAMINGHAM, MA / ACCESS Newswire / February 27, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting being held March 12 - 14, 2025 in San Diego, CA and virtually.
Details for the presentation are as follows:
Abstract Number: 123
Title: DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma
Presenter: Alexey Stepanov, PhD, Institute Investigator at The Scripps Research Institute
Date & Time: Wednesday, March 12, 2025 at 5:10 p.m. - 6:45p.m. PT
For more information, please visit the conference website here.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.
Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
[email protected]
SOURCE: Xenetic Biosciences, Inc.
View the original press release on ACCESS Newswire
S.Jackson--AT
